Preventing cardiovascular and renal complications in patients with type 2 diabetes and microalbuminuria: the GP-Prompt study

An implementation strategy for reducing cardiac and renal complications in people with type 2 diabetes: the GP-Prompt study

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN14918517

Enrollment

Registered

2015-06-09

Start date

2015-06-15

Completion date

Unknown

Last updated

2021-03-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

The intervention being tested is aimed at general practitioners and practice nurses. The intervention will support practices in managing patients with type 2 diabetes and microalbuminuria. Not Applicable

Interventions

The intervention consists of three separate parts: 1. A software alert/template: the software alert will sit on the GP Practice computer and will trigger when eligible patients attend

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: We aim to recruit 24 practices (12 intervention & 12 control) we will collect anonymised data from eligible patients registered at participating practices. Patients will be eligible if they have type 2 diabetes and microalbuminuria and are not excepted from quality outcomes framework (QOF) (whole domain diabetes) for any reason.

Exclusion criteria

Exclusion criteria: 1. GP practices not located in Leicester City CCG, Leicester county east CCG or Leicester county west CCG will not be invited to take part in the study 2. GP practices with a list size of <6500 patients will not be invited to take part in the study

Design outcomes

Primary

Measure	Time frame
Proportion (%) of patients meeting both of the following targets: BP <130/80 mmHg and total cholesterol <3.5mmol/l measured 24 months post-intervention.	—

Secondary

Measure	Time frame
1. Incidence of CV events and all-cause mortality 2. Glycaemic control assessed by HbA1c 3. Progression in microalbuminuria assessed via albumin-creatinine ratio (ACR) 4. Kidney function measured via estimated glomerular filtration rate (eGFR) 5. Current type 2 diabetes mellitus medications (use of metformin, Sulphonylureas (SUs), insulin, thiazolidinediones (TZD), glucagon-like peptide-1 (GLP1), dipeptidyl peptidase-4 inhibitor (DPP4) or sodium-glucose linked transporters (SGLT2)) 6. Current BP or cholesterol medications (use of ACE inhibitors, ARBs, beta blockers, alpha blockers, aspirin, statins or exenatide) 7. Current smoking status	—

Measure

Time frame

1. Incidence of CV events and all-cause mortality 2. Glycaemic control assessed by HbA1c 3. Progression in microalbuminuria assessed via albumin-creatinine ratio (ACR) 4. Kidney function measured via estimated glomerular filtration rate (eGFR) 5. Current type 2 diabetes mellitus medications (use of metformin, Sulphonylureas (SUs), insulin, thiazolidinediones (TZD), glucagon-like peptide-1 (GLP1), dipeptidyl peptidase-4 inhibitor (DPP4) or sodium-glucose linked transporters (SGLT2)) 6. Current BP or cholesterol medications (use of ACE inhibitors, ARBs, beta blockers, alpha blockers, aspirin, statins or exenatide) 7. Current smoking status

—

Countries

United Kingdom

Contacts

Public ContactAndrew Willis

aw187@le.ac.uk+44 (0)1162588995

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Mar 6, 2026